secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2026-05-13T20:18:25+00:00
Accession:  0001641489-26-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics reports Q1 net income of $24.1M on $36.8M license revenue; CATT1 enrollment on track
--------------------------------------------------------------------------------

- Net income attributable to shareholders of $24.1M ($1.94 basic EPS) vs. net loss of $5.1M a year ago.
- Revenue of $36.8M from Newsoara license amendment; $20M upfront plus up to ~$115M milestones.
- Cash $98.1M at March 31, 2026, up from $88.9M; company says funds through CATT1 topline readout.
- Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes — enrollment on track for completion in Q3 2026.
- R&D expenses $9.0M (vs. $2.8M) driven by CATT1 trial investment; G&A $4.6M (vs. $3.7M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148926000019/0001641489-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148926000019/vtvt-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001641489-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer